How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
About 50% of High Grade Serous Ovarian Cancer exhibit a high degree of genomic instability due to mutation of genes involved in Homologous Recombination (HRD) and such defect accounts for synthetic lethality mechanism of PARP inhibitors (PARP-i). Several clinical trials have shown how BRCA and HRD m...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1335196/full |
| _version_ | 1827323232646070272 |
|---|---|
| author | Martina Arcieri Martina Arcieri Veronica Tius Claudia Andreetta Stefano Restaino Anna Biasioli Elena Poletto Giuseppe Damante Giuseppe Damante Alfredo Ercoli Lorenza Driul Lorenza Driul Anna Fagotti Domenica Lorusso Giovanni Scambia Giuseppe Vizzielli Giuseppe Vizzielli |
| author_facet | Martina Arcieri Martina Arcieri Veronica Tius Claudia Andreetta Stefano Restaino Anna Biasioli Elena Poletto Giuseppe Damante Giuseppe Damante Alfredo Ercoli Lorenza Driul Lorenza Driul Anna Fagotti Domenica Lorusso Giovanni Scambia Giuseppe Vizzielli Giuseppe Vizzielli |
| author_sort | Martina Arcieri |
| collection | DOAJ |
| description | About 50% of High Grade Serous Ovarian Cancer exhibit a high degree of genomic instability due to mutation of genes involved in Homologous Recombination (HRD) and such defect accounts for synthetic lethality mechanism of PARP inhibitors (PARP-i). Several clinical trials have shown how BRCA and HRD mutational status profoundly affect first line chemotherapy as well as response to maintenance therapy with PARP-i, hence Progression Free Survival and Overall Survival. Consequently, there is urgent need for the development of increasingly reliable HRD tests, overcoming present limitations, as they play a key role in the diagnostic and therapeutic process as well as have a prognostic and predictive value. In this review we offer an overview of the state of the art regarding the actual knowledge about BRCA and HRD mutational status, the rationale of PARPi use and HRD testing (current and in development assays) and their implications in clinical practice and in the treatment decision process, in order to optimize and choose the best tailored therapy in patients with ovarian cancer. |
| first_indexed | 2024-04-25T01:41:55Z |
| format | Article |
| id | doaj.art-3d1bed078930434ca0103b78ab067442 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-25T01:41:55Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-3d1bed078930434ca0103b78ab0674422024-03-08T04:46:18ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-03-011410.3389/fonc.2024.13351961335196How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literatureMartina Arcieri0Martina Arcieri1Veronica Tius2Claudia Andreetta3Stefano Restaino4Anna Biasioli5Elena Poletto6Giuseppe Damante7Giuseppe Damante8Alfredo Ercoli9Lorenza Driul10Lorenza Driul11Anna Fagotti12Domenica Lorusso13Giovanni Scambia14Giuseppe Vizzielli15Giuseppe Vizzielli16Clinic of Obstetrics and Gynecology, “S. Maria della Misericordia” University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, ItalyDepartment of Biomedical, Dental, Morphological and Functional Imaging Science, University of Messina, Messina, ItalyMedical Area Department (DAME), in Department of Medicine (DMED), University of Udine, Udine, ItalyDepartment of Medical Oncology, “S. Maria della Misericordia” University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, ItalyClinic of Obstetrics and Gynecology, “S. Maria della Misericordia” University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, ItalyClinic of Obstetrics and Gynecology, “S. Maria della Misericordia” University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, ItalyDepartment of Medical Oncology, “S. Maria della Misericordia” University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, ItalyMedical Area Department (DAME), in Department of Medicine (DMED), University of Udine, Udine, ItalyMedical Genetics Institute, “S. Maria della Misericordia” University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, ItalyDepartment of Human Pathology in Adult and Childhood “G. Barresi”, Unit of Gynecology and Obstetrics, University of Messina, Messina, ItalyClinic of Obstetrics and Gynecology, “S. Maria della Misericordia” University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, ItalyMedical Area Department (DAME), in Department of Medicine (DMED), University of Udine, Udine, ItalyDipartimento per le Scienze Della Salute Della Donna, del Bambino e di Sanità Pubblica, UOC Ginecologia Oncologica, in Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyDipartimento per le Scienze Della Salute Della Donna, del Bambino e di Sanità Pubblica, UOC Ginecologia Oncologica, in Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyDipartimento per le Scienze Della Salute Della Donna, del Bambino e di Sanità Pubblica, UOC Ginecologia Oncologica, in Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyClinic of Obstetrics and Gynecology, “S. Maria della Misericordia” University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, ItalyMedical Area Department (DAME), in Department of Medicine (DMED), University of Udine, Udine, ItalyAbout 50% of High Grade Serous Ovarian Cancer exhibit a high degree of genomic instability due to mutation of genes involved in Homologous Recombination (HRD) and such defect accounts for synthetic lethality mechanism of PARP inhibitors (PARP-i). Several clinical trials have shown how BRCA and HRD mutational status profoundly affect first line chemotherapy as well as response to maintenance therapy with PARP-i, hence Progression Free Survival and Overall Survival. Consequently, there is urgent need for the development of increasingly reliable HRD tests, overcoming present limitations, as they play a key role in the diagnostic and therapeutic process as well as have a prognostic and predictive value. In this review we offer an overview of the state of the art regarding the actual knowledge about BRCA and HRD mutational status, the rationale of PARPi use and HRD testing (current and in development assays) and their implications in clinical practice and in the treatment decision process, in order to optimize and choose the best tailored therapy in patients with ovarian cancer.https://www.frontiersin.org/articles/10.3389/fonc.2024.1335196/fullovarian cancerhomologous recombination deficiencyBRCA proteinBRCAnessHRD testingPARP inhibitors |
| spellingShingle | Martina Arcieri Martina Arcieri Veronica Tius Claudia Andreetta Stefano Restaino Anna Biasioli Elena Poletto Giuseppe Damante Giuseppe Damante Alfredo Ercoli Lorenza Driul Lorenza Driul Anna Fagotti Domenica Lorusso Giovanni Scambia Giuseppe Vizzielli Giuseppe Vizzielli How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature Frontiers in Oncology ovarian cancer homologous recombination deficiency BRCA protein BRCAness HRD testing PARP inhibitors |
| title | How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature |
| title_full | How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature |
| title_fullStr | How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature |
| title_full_unstemmed | How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature |
| title_short | How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature |
| title_sort | how brca and homologous recombination deficiency change therapeutic strategies in ovarian cancer a review of literature |
| topic | ovarian cancer homologous recombination deficiency BRCA protein BRCAness HRD testing PARP inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1335196/full |
| work_keys_str_mv | AT martinaarcieri howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT martinaarcieri howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT veronicatius howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT claudiaandreetta howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT stefanorestaino howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT annabiasioli howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT elenapoletto howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT giuseppedamante howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT giuseppedamante howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT alfredoercoli howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT lorenzadriul howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT lorenzadriul howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT annafagotti howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT domenicalorusso howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT giovanniscambia howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT giuseppevizzielli howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature AT giuseppevizzielli howbrcaandhomologousrecombinationdeficiencychangetherapeuticstrategiesinovariancancerareviewofliterature |